Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Goodwill (2016 - 2025)

CytomX Therapeutics' Goodwill history spans 12 years, with the latest figure at $949000.0 for Q4 2025.

  • For Q4 2025, Goodwill changed 0.0% year-over-year to $949000.0; the TTM value through Dec 2025 reached $949000.0, changed 0.0%, while the annual FY2025 figure was $949000.0, 0.0% changed from the prior year.
  • Goodwill reached $949000.0 in Q4 2025 per CTMX's latest filing, roughly flat from $949000.0 in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $949000.0 in Q1 2021 to a low of $949000.0 in Q1 2021.
  • Average Goodwill over 5 years is $949000.0, with a median of $949000.0 recorded in 2021.
  • The largest YoY upside for Goodwill was 0.0% in 2021 against a maximum downside of 0.0% in 2021.
  • A 5-year view of Goodwill shows it stood at $949000.0 in 2021, then changed by 0.0% to $949000.0 in 2022, then changed by 0.0% to $949000.0 in 2023, then changed by 0.0% to $949000.0 in 2024, then changed by 0.0% to $949000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Goodwill are $949000.0 (Q4 2025), $949000.0 (Q3 2025), and $949000.0 (Q2 2025).